<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lauren B Elman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leo McCluskey, MD, MBE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Colin Quinn, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Amyotrophic lateral sclerosis (ALS), first described by Charcot in the 19<sup>th</sup> century, is a relentlessly progressive, presently incurable neurodegenerative disorder that causes muscle weakness, disability, and eventually death. ALS is also known as Lou Gehrig's disease, after the famous New York Yankee baseball player who was affected with the disorder [<a href="#rid1">1-3</a>]. Motor neuron disease (MND) is the preferred term in the United Kingdom, but ALS and MND are sometimes used interchangeably in the United States.</p><p>This topic will review the clinical features of ALS. Other aspects of ALS are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5156.html" rel="external">"Epidemiology and pathogenesis of amyotrophic lateral sclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5138.html" rel="external">"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5128.html" rel="external">"Disease-modifying treatment of amyotrophic lateral sclerosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5129.html" rel="external">"Symptom-based management of amyotrophic lateral sclerosis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLINICOPATHOLOGIC FEATURES</span><span class="headingEndMark"> — </span>The clinical hallmark of ALS is the combination of upper and lower motor neuron signs and symptoms.</p><p class="bulletIndent1"><span class="glyph">●</span>The upper motor neuron findings of weakness with slowness, hyperreflexia, and spasticity result from degeneration of frontal lobe motor neurons located in the motor strip (Brodmann area 4) and their axons traversing the corona radiata, internal capsule, cerebral peduncles, pontine base, medullary pyramids, and the lateral corticospinal tracts of the spinal cord. At autopsy, the dorsolateral area of the spinal cord, the region containing the lateral corticospinal tract, is gliotic and hardened or sclerotic to palpation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The lower motor neuron findings of weakness, atrophy or amyotrophy, and fasciculations are a direct consequence of degeneration of lower motor neurons in the brainstem and spinal cord producing muscle denervation.</p><p></p><p>The neuropathology of ALS is characterized by pathologic inclusions within both upper and lower motor neurons and glia. Such inclusions also occur in nonmotor frontal and temporal cortical neurons and in more widespread areas of the brain not typically associated with classic symptoms of ALS. Inclusions stain positively for ubiquitin; a large subset also stains positively for TAR DNA-binding protein (TDP-43) and smaller subsets stain for fused in sarcoma (FUS) protein and optineurin. (See  <a class="medical medical_review" href="/d/html/5156.html" rel="external">"Epidemiology and pathogenesis of amyotrophic lateral sclerosis", section on 'Intracellular inclusions'</a>.)</p><p>The term "amyotrophic lateral sclerosis" is derived from the combination of the clinical examination finding of muscle atrophy with the pathologic finding of hardening of the lateral corticospinal tracts [<a href="#rid2">2-7</a>]. While it was once presumed to be a pure motor disorder, it has become increasingly apparent that degeneration of other brain regions such as frontal and temporal cortical neurons may also occur as part of the clinicopathologic spectrum of ALS. (See <a class="local">'ALS-plus syndrome'</a> below and <a class="local">'Cognitive symptoms'</a> below and <a class="local">'Autonomic symptoms'</a> below and <a class="local">'Parkinsonism and supranuclear gaze palsy'</a> below and <a class="local">'Sensory symptoms'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">SPECTRUM OF MOTOR NEURON DISEASE</span><span class="headingEndMark"> — </span>ALS is one of multiple degenerative motor neuron diseases that are clinically defined, based on the involvement of upper and/or lower motor neurons [<a href="#rid1">1,2,8</a>]. ALS is the most common form of motor neuron disease and includes upper and lower motor neuron pathology.</p><p class="headingAnchor" id="H4"><span class="h2">Progressive muscular atrophy</span><span class="headingEndMark"> — </span>Progressive muscular atrophy is a progressive lower motor neuron disorder. Some experts believe it represents a form of ALS [<a href="#rid9">9,10</a>].</p><p>When the disease remains confined to the lower motor neuron, survival may be prolonged compared with classic ALS. In the largest study, 91 patients initially diagnosed with progressive muscular atrophy had a longer median survival than 871 patients with ALS (48 versus 36 months) [<a href="#rid9">9</a>]. However, on Kaplan-Meier estimates, the survival curves of progressive muscular atrophy and ALS crossed at approximately 80 months. Thereafter, the estimated survival in progressive muscular atrophy was approximately the same as that of ALS. In an earlier series, 37 patients with progressive muscular atrophy had a median survival of 56 months [<a href="#rid11">11</a>].</p><p>Some individuals who present with isolated lower motor neuron signs never develop clinical upper motor neuron signs. Many, however, develop upper motor neuron signs later in their clinical course, at which point the disease is called lower motor neuron-onset ALS. In the series cited above, upper motor neuron signs developed in 20 of 91 patients (22 percent) initially diagnosed with progressive muscular atrophy [<a href="#rid9">9</a>]. Typically, upper motor neuron involvement occurred within two years of symptom onset.</p><p>At autopsy, patients with progressive muscular atrophy who never developed clinically apparent upper motor neuron signs frequently have upper motor neuron pathology, including corticospinal tract abnormalities and TDP-43 positive inclusions in motor cortex, in a pattern identical to that of ALS [<a href="#rid6">6,12</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Primary lateral sclerosis</span><span class="headingEndMark"> — </span>Primary lateral sclerosis is a progressive isolated upper motor neuron neurodegenerative disorder [<a href="#rid13">13</a>]. Cases of pure upper motor neuron disease make up a small percentage of ALS/motor neuron disease [<a href="#rid14">14,15</a>]. New diagnostic criteria for definite PLS require isolated upper motor neuron signs for greater than four years [<a href="#rid16">16</a>].</p><p>Compared with ALS, primarily lateral sclerosis is characterized by slower progression, lack of weight loss, and absence of lower motor neuron findings on examination or electromyography in the first four years after symptom onset [<a href="#rid16">16-20</a>]. Symptoms usually begin in the lower extremities and may be symmetric, with impaired gait and spasticity and hyperreflexia on examination. Corticobulbar symptoms (eg, dysarthria, pseudobulbar affect) typically develop later in the course. Many patients also have bladder instability and urinary retention. The early phase of disease has significant clinical overlap with hereditary spastic paraparesis. (See  <a class="medical medical_review" href="/d/html/5138.html" rel="external">"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease", section on 'Hereditary spastic paraplegia'</a>.)</p><p>Patients who develop delayed lower motor neuron findings are typically referred to as having upper motor neuron-onset ALS. Reports of pathology in clinically defined primary lateral sclerosis are limited, but disease pathologically isolated to the upper motor neuron has been described [<a href="#rid21">21-24</a>].</p><p>Pure primary lateral sclerosis and upper motor neuron-dominant ALS appear to have a more benign prognosis than typical ALS [<a href="#rid13">13,19,20,25</a>]. Survival tends to be longer and disease progression slower in patients classified as primary lateral sclerosis compared with ALS controls [<a href="#rid17">17</a>]. Survival for patients with upper motor neuron-dominant ALS is intermediate between that of primary lateral sclerosis and classic ALS.</p><p class="headingAnchor" id="H6"><span class="h2">Progressive bulbar palsy</span><span class="headingEndMark"> — </span>Progressive bulbar palsy is a progressive upper and lower motor neuron disorder of cranial muscles. Symptoms remain isolated to the bulbar segment in progressive bulbar palsy. However, patients initially diagnosed with progressive bulbar palsy may commonly develop upper and lower motor neuron signs and symptoms involving other body regions and are then classified as having bulbar-onset ALS [<a href="#rid26">26</a>]. There have been no reports of specific pathology in progressive bulbar palsy [<a href="#rid1">1-3,27</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Flail arm syndrome</span><span class="headingEndMark"> — </span>The flail arm syndrome (also called brachial amyotrophic diplegia) is characterized by progressive lower motor neuron weakness and wasting that predominantly affects the proximal arm [<a href="#rid28">28-30</a>]. It usually begins proximally and spreads distally to the point where arm and hand function is severely impaired. It is often asymmetric. Patients presenting with the flail arm variant of ALS have a longer survival time and a slower rate of progression both to the spread of signs and symptoms in other body segments and to development of respiratory muscle weakness [<a href="#rid31">31,32</a>]. </p><p class="headingAnchor" id="H28382562"><span class="h2">Flail leg syndrome</span><span class="headingEndMark"> — </span>The flail leg syndrome (also called the pseudo-polyneuritic variant of ALS/motor neuron disease) is characterized by progressive lower motor neuron weakness and wasting with onset in the distal leg [<a href="#rid31">31,33</a>]. Patients presenting with the flail leg syndrome have a lower rate of comorbid dementia, a longer survival time, and a slower rate of progression to involvement of other body segments and of the development of respiratory muscle weakness [<a href="#rid31">31,32</a>].</p><p class="headingAnchor" id="H8"><span class="h2">ALS-plus syndrome</span><span class="headingEndMark"> — </span>Classically defined, ALS is considered a degenerative disorder of the upper and lower motor neurons and does not include symptoms or signs outside of the voluntary motor system. However, some patients have the clinical features of ALS along with features of other disorders such as frontotemporal dementia (FTD), autonomic insufficiency, parkinsonism, supranuclear gaze paresis, and/or sensory loss. Such patients are considered to have ALS-plus syndrome. Of these, ALS-FTD is the most common.</p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL SYMPTOMS AND SIGNS</span><span class="headingEndMark"> — </span>The loss of motor neurons results in the primary clinical symptoms and signs of ALS. These may produce impairment affecting limb  (<a class="graphic graphic_table graphicRef72454" href="/d/graphic/72454.html" rel="external">table 1</a>), bulbar  (<a class="graphic graphic_table graphicRef75146" href="/d/graphic/75146.html" rel="external">table 2</a>), axial  (<a class="graphic graphic_table graphicRef67913" href="/d/graphic/67913.html" rel="external">table 3</a>), and respiratory  (<a class="graphic graphic_table graphicRef58537" href="/d/graphic/58537.html" rel="external">table 4</a>) function.</p><p>Differences in site and segment (cranial, cervical, thoracic, or lumbosacral) of onset, pattern and speed of spread, and the degree of upper and/or lower motor neuron dysfunction produce a disorder that is remarkably variable between individuals.</p><p class="headingAnchor" id="H10"><span class="h2">Initial presentation</span><span class="headingEndMark"> — </span>The initial clinical manifestation of ALS may occur in any body segment (bulbar, cervical, thoracic, or lumbosacral) and may manifest as upper motor neuron (see <a class="local">'Upper motor neuron symptoms'</a> below) or lower motor neuron (see <a class="local">'Lower motor neuron symptoms'</a> below) symptoms or signs. Asymmetric limb weakness is the most common presentation of ALS (80 percent). Upper-extremity onset is most often heralded by hand weakness but may begin in the shoulder girdle muscles. The "split-hand syndrome" describes a frequent pattern of weakness and atrophy in ALS that predominantly involves the median- and ulnar-innervated lateral (thenar) hand intrinsic muscles with relative sparing of the medial (hypothenar) muscles [<a href="#rid34">34-36</a>]. Lower-extremity onset of ALS most often begins with weakness of foot dorsiflexion (foot drop), while proximal pelvic girdle onset is less common. </p><p>Twenty percent of patients will have onset in the bulbar segment, which most often presents with either dysarthria or dysphagia.</p><p>Less common patterns of ALS onset include respiratory muscle weakness (1 to 3 percent) [<a href="#rid37">37</a>], generalized weakness in the limbs and bulbar muscles (1 to 9 percent), axial onset with head drop or truncal extension weakness, and weight loss with muscle atrophy, fasciculations, and cramps [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H11"><span class="h2">Upper motor neuron symptoms</span><span class="headingEndMark"> — </span>Loss of upper motor neurons results in slowness of movement, incoordination, and stiffness with relatively little overt weakness. Arm or hand upper motor neuron symptoms include poor dexterity with resulting difficulty performing activities of daily living. Leg upper motor neuron symptoms manifest as a spastic gait with poor balance and may include spontaneous leg flexor spasms and ankle clonus  (<a class="graphic graphic_table graphicRef72454" href="/d/graphic/72454.html" rel="external">table 1</a>).</p><p>Dysarthria and dysphagia are the most common bulbar upper motor neuron symptoms  (<a class="graphic graphic_table graphicRef75146" href="/d/graphic/75146.html" rel="external">table 2</a>). Upper motor neuron or spastic dysarthria produces a characteristically strained vocal quality with slow speech. Upper motor neuron dysphagia results from slow and discoordinated contraction of the swallowing muscles, which may lead to coughing and choking.</p><p>Another frequent bulbar upper motor neuron symptom is the syndrome of the pseudobulbar affect [<a href="#rid38">38,39</a>]. This is manifested as inappropriate laughing, crying, or yawning. This may occur as an early manifestation of ALS or may develop during the disease course. The observed affect is often mood incongruent or may be triggered by a minor emotional stimulus. Patients also report difficulty with cessation of the laughing or crying once it has begun. (See  <a class="medical medical_review" href="/d/html/5129.html" rel="external">"Symptom-based management of amyotrophic lateral sclerosis", section on 'Pseudobulbar affect'</a>.)</p><p>Upper motor neuron bulbar dysfunction may also result in laryngospasm. This is a short-lived (usually &lt;30 seconds) reflex closure of the larynx that most often occurs in response to aspiration of food particles or liquids, including saliva. The patient typically describes a squeezing feeling in the throat accompanied by impaired inspiration and difficulty speaking; there may be audible stridor.</p><p>Additional manifestations of upper motor neuron bulbar dysfunction may include increased masseter tone and difficulty opening the mouth. When severe, this is referred to as trismus. At times there may be involuntary jaw clenching with biting of the sides of the tongue and cheeks.</p><p>Axial upper motor neuron dysfunction may contribute to stiffness and imbalance  (<a class="graphic graphic_table graphicRef67913" href="/d/graphic/67913.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H12"><span class="h2">Lower motor neuron symptoms</span><span class="headingEndMark"> — </span>Loss of lower motor neurons results in weakness, usually accompanied by atrophy  (<a class="graphic graphic_movie graphicRef53274" href="/d/graphic/53274.html" rel="external">movie 1</a>) and fasciculations  (<a class="graphic graphic_movie graphicRef66062" href="/d/graphic/66062.html" rel="external">movie 2</a> and <a class="graphic graphic_movie graphicRef63510" href="/d/graphic/63510.html" rel="external">movie 3</a>). Muscle cramps are also common [<a href="#rid40">40</a>].</p><p>Hand weakness causes difficulty manipulating small objects (buttons, zippers, coins) and using writing instruments  (<a class="graphic graphic_table graphicRef72454" href="/d/graphic/72454.html" rel="external">table 1</a>). Proximal arm weakness results in difficulty elevating the arm to the level of the mouth or above the head. This can produce difficulty with bathing, dressing, grooming, and eating. Foot and ankle weakness results in tripping, a slapping gait, and falling. Proximal leg weakness results in difficulty arising from chairs, climbing stairs, and getting off the floor. Balance may also be adversely affected.</p><p>Dysarthria and dysphagia can also result from lower motor neuron damage  (<a class="graphic graphic_table graphicRef75146" href="/d/graphic/75146.html" rel="external">table 2</a>). Dysarthria may result from weakness of the tongue, lips, or palate. The speech is usually slurred and may have a nasal quality. Hoarseness may be caused by associated vocal cord weakness. Dysphagia results from tongue weakness with disruption of the oral phase of swallowing or from pharyngeal constrictor weakness with disruption of the pharyngeal phase of swallowing or both. Tongue weakness may lead to pocketing of food between the cheeks and gums. Pharyngeal weakness often manifests as coughing and choking on food, liquids, or secretions such as saliva or mucus. Aspiration may result.</p><p>Lower motor neuron weakness of the upper face may produce incomplete eye closure  (<a class="graphic graphic_table graphicRef75146" href="/d/graphic/75146.html" rel="external">table 2</a>). Lower facial weakness is more common and may result in poor lip seal that may contribute to drooling or sialorrhea, particularly in patients with associated swallowing difficulty. Lower motor neuron weakness of the masseter can cause difficulty chewing; when severe, it may produce an inability to close the mouth. Lower motor neuron weakness of the pterygoids may produce difficulty opening the mouth and moving the jaw from side to side. Severe masseter and pterygoid weakness may contribute to disarticulation of the temporomandibular joint.</p><p>Lower motor neuron weakness affecting the trunk and spine may produce difficulty holding up the head and difficulty maintaining an erect posture as well as abdominal protuberance  (<a class="graphic graphic_table graphicRef67913" href="/d/graphic/67913.html" rel="external">table 3</a>).</p><p>Lower motor neuron weakness of the diaphragm produces progressive dyspnea with decreasing amounts of effort culminating in dyspnea at rest and with talking along with reduced vocal volume  (<a class="graphic graphic_table graphicRef58537" href="/d/graphic/58537.html" rel="external">table 4</a>). Diaphragmatic weakness may also result in orthopnea and sleep disordered breathing.</p><p>Extraocular motor neurons residing in the nuclei of the oculomotor (CN III), trochlear (CN IV), and abducens (CN VI) nerves are spared until very late in the disease course. Patients who choose long-term mechanical ventilation have a longer clinical course that can include progressive difficulty with ocular motility. This may culminate in the locked-in state, a clinical condition characterized by inability to move any voluntary muscle. Such patients may be alert and awake but completely unable to communicate.</p><p class="headingAnchor" id="H13"><span class="h2">Cognitive symptoms</span><span class="headingEndMark"> — </span>There is a well-established link between ALS and frontotemporal behavioral and executive dysfunction that may precede or follow the onset of upper and/or lower motor neuron dysfunction [<a href="#rid41">41-46</a>]. The pattern of cognitive impairment includes problems with executive function, language, grammar, and verbal fluency with relative sparing of memory and visuospatial function. Common behavioral changes include apathy, loss of empathy, changes in eating behaviors, disinhibition, and perseveration.</p><p>While most patients with ALS do not have overt dementia, some degree of cognitive and behavioral dysfunction is present in approximately one-third to one-half of patients and becomes increasingly common with advancing disease [<a href="#rid44">44,47,48</a>]. In a cross-sectional study of 161 patients with ALS, the rate of ALS-specific cognitive impairment as measured by the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) ranged from 18 percent among patients with King's clinical stage 1 and 2 disease to 39 percent among those with stage 4 disease (nutritional or respiratory failure) [<a href="#rid47">47</a>]. Behavioral impairment was present in 18 and 27 percent of patients with stage 1 and 2 disease, respectively, and 65 percent of those with stage 4 disease. Bulbar dysfunction is an independent predictor of cognitive and behavioral problems [<a href="#rid47">47,48</a>]. (See <a class="local">'Clinical patterns of progression'</a> below.)</p><p>Approximately 15 percent of patients with ALS meet criteria for frontotemporal dementia (FTD) [<a href="#rid41">41</a>]. Retrospective data suggest that ALS with FTD may be associated with shorter survival than ALS with normal executive and behavioral function [<a href="#rid49">49</a>]. ALS with FTD may be familial or sporadic. (See  <a class="medical medical_review" href="/d/html/5176.html" rel="external">"Familial amyotrophic lateral sclerosis", section on 'C9ORF72 gene'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Autonomic symptoms</span><span class="headingEndMark"> — </span>Autonomic symptoms may occur in ALS as the disease progresses, although they are typically mild [<a href="#rid50">50</a>]. Constipation occurs frequently and is likely multifactorial. Delayed colonic motility has been demonstrated. Dysphagia for thin liquids related to pharyngeal muscle weakness may lead to dehydration that can exacerbate constipation. Symptoms of early satiety and bloating consistent with delayed gastric emptying also occur as the disease progresses [<a href="#rid51">51-53</a>]. Urinary urgency without incontinence is common, while incontinence is uncommon.</p><p>Some patients complain of excessive sweating, but whether a disorder of sweating occurs in association with ALS is controversial [<a href="#rid54">54,55</a>]. Small studies have demonstrated abnormal sudomotor function, including one study that showed hyperhidrosis early in ALS, with decline in later-stage disease [<a href="#rid50">50,56,57</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Parkinsonism and supranuclear gaze palsy</span><span class="headingEndMark"> — </span>Extrapyramidal symptoms and signs of parkinsonism may precede or follow the upper and lower motor neuron symptoms. These extrapyramidal features may include facial masking, tremor, bradykinesia, and postural instability [<a href="#rid58">58,59</a>]. In a single-center cohort of 550 patients with ALS, ocular motility abnormalities were found in the majority of patients, and extrapyramidal abnormalities were seen in approximately one quarter [<a href="#rid60">60,61</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Sensory symptoms</span><span class="headingEndMark"> — </span>Sensory symptoms may occur in 20 to 30 percent of patients with ALS [<a href="#rid1">1,62</a>]. It is not uncommon for patients with ALS, particularly those with distal limb onset of symptoms, to complain of tingling paresthesia (see <a class="local">'Pain'</a> below). When queried regarding sensory loss, these patients typically will deny loss of sensation, and physical examination does not detect objective sensory loss. At times, however, objective sensory loss may occur as part of an ALS-plus syndrome and may precede or follow motor symptoms. Electrophysiologic studies may demonstrate reduction of amplitudes on sensory nerve conduction and/or slowing of dorsal column conduction on somatosensory evoked potential testing, even in patients without sensory findings on examination [<a href="#rid62">62-66</a>]. Autopsy may demonstrate evidence of degeneration within sensory pathways in individuals with and without sensory loss.</p><p class="headingAnchor" id="H2435467958"><span class="h2">Pain</span><span class="headingEndMark"> — </span>Nociceptive pain in ALS can arise from a variety of causes that include reduced mobility, muscle cramps, muscle spasticity, and comorbid conditions [<a href="#rid67">67,68</a>]. Reduced mobility predisposes to skin breakdown and musculoskeletal pain. Respiratory symptoms and interventions can lead to pain, with discomfort and skin breakdown from noninvasive ventilation masks, and irritation from suctioning of secretions and weighing and pulling of ventilator hoses. In addition, pain with neuropathic features (eg, paresthesia, allodynia, hyperalgesia) may affect some patients with ALS. Although generally of mild to moderate intensity, pain in the later stages of ALS can be severe enough to necessitate treatment with analgesic and sedative medications [<a href="#rid67">67,69,70</a>].</p><p>A systematic review published in 2017 found that prevalence of pain in patients with ALS ranged from 15 to 85 percent [<a href="#rid67">67</a>]. The inconsistency of these findings was attributed to the heterogeneous methods and relatively small size of the underlying studies.</p><p class="headingAnchor" id="H17"><span class="h2">Clinical patterns of progression</span><span class="headingEndMark"> — </span>ALS is a relentlessly progressive disorder with a clinical course that is generally linear, with a relatively constant slope. While the rate of progression between individuals is variable, the history generally reflects gradual and progressive worsening over time without intervening remissions or exacerbations.</p><p>Symptoms initially spread within the segment of onset and then to other regions in a relatively predictable pattern [<a href="#rid1">1,23,71,72</a>]. In patients with unilateral arm onset, the most common (approximately 60 to 70 percent of patients) pattern of spread is to the contralateral arm, then to the ipsilateral leg, then to the contralateral remaining leg, and then to the bulbar muscles. In patients with unilateral leg onset, the most common (approximately 60 to 70 percent of patients) pattern of spread is to the contralateral leg, then to the ipsilateral arm, then to the contralateral arm, and then to bulbar muscles. In patients with bulbar onset, the most common pattern of spread is to one arm and then to the contralateral arm [<a href="#rid1">1,23</a>].</p><p>Multiple clinical staging systems have been developed to help identify an objective measure of disease progression. They may also help guide treatment decisions and aid in prognostication. Commonly used staging systems include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The King's College ALS staging system classifies disease progression based on the number of body regions involved as well as the need for swallowing or respiratory support [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The MiToS system defines the progressive loss of independence in key functional domains: walking/self-care, swallowing, communicating, and breathing.</p><p></p><p>Both systems primarily use information that can be gathered from the revised ALS Functional Rating Scale, the most commonly used measure in ALS clinical trials.</p><p class="headingAnchor" id="H18"><span class="h2">Life-threatening features</span><span class="headingEndMark"> — </span>The progressive course of ALS may eventually produce one or both of the life-threatening aspects of the disease: neuromuscular respiratory failure and dysphagia. Respiratory muscle weakness may be the first manifestation of the disease but more commonly develops after months or years of progressive limb and/or bulbar muscle weakness.</p><p>Progressive neuromuscular respiratory failure is the most common cause of death in ALS. In the United States, 5 to 10 percent of patients choose tracheostomy and permanent ventilation when respiratory compromise becomes severe.</p><p>Similarly, progressive dysphagia may be one of the initial manifestations of the disease or may develop after months or years of progressive limb and/or other bulbar weakness. Dysphagia poses a risk for aspiration of food, liquids, or secretions with resultant pneumonia and may also lead to malnutrition and dehydration. These conditions can be minimized in patients who choose gastrostomy tube insertion and with aggressive management of secretions. (See  <a class="medical medical_review" href="/d/html/5129.html" rel="external">"Symptom-based management of amyotrophic lateral sclerosis", section on 'Management of swallowing and nutrition'</a> and  <a class="medical medical_review" href="/d/html/85949.html" rel="external">"Swallowing disorders and aspiration in palliative care: Definition, pathophysiology, etiology, and consequences"</a> and  <a class="medical medical_review" href="/d/html/95508.html" rel="external">"Swallowing disorders and aspiration in palliative care: Assessment and strategies for management"</a>.)</p><p>The median survival from the time of symptom onset is three to five years. However, approximately 10 percent of ALS patients can live 10 years or more. Survival beyond 20 years is possible but rare and in part depends on treatment decisions made by patients and their families.</p><p class="headingAnchor" id="H3875631739"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118906.html" rel="external">"Society guideline links: Motor neuron disease"</a>.)</p><p class="headingAnchor" id="H248867201"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/86016.html" rel="external">"Patient education: Amyotrophic lateral sclerosis (ALS) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1961991255"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/d/html/139137.html" rel="external">"Patient perspective: Amyotrophic lateral sclerosis (ALS)"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Characteristic clinical features</strong> – The clinical hallmark of amyotrophic lateral sclerosis (ALS) is the combination of upper motor neuron and lower motor neuron signs and symptoms. Upper motor neuron findings result from degeneration of frontal lobe motor neurons and the corticospinal tract. The lower motor neuron findings are a direct consequence of degeneration of lower motor neurons in the brainstem and spinal cord. (See <a class="local">'Clinicopathologic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of clinical disorder</strong> – ALS is the most common form of motor neuron disease and includes upper and lower motor neuron pathology. The spectrum of motor neuron disease also includes other conditions that may be variants of ALS or may represent different patterns of evolution in ALS. These include (see <a class="local">'Spectrum of motor neuron disease'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progressive muscular atrophy</p><p class="bulletIndent2"><span class="glyph">•</span>Primary lateral sclerosis</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive bulbar palsy</p><p class="bulletIndent2"><span class="glyph">•</span>Flail arm and flail leg syndromes</p><p class="bulletIndent2"><span class="glyph">•</span>ALS-plus syndromes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical symptoms</strong> – The primary clinical symptoms and signs of ALS may produce impairment affecting limb  (<a class="graphic graphic_table graphicRef72454" href="/d/graphic/72454.html" rel="external">table 1</a>), bulbar  (<a class="graphic graphic_table graphicRef75146" href="/d/graphic/75146.html" rel="external">table 2</a>), axial  (<a class="graphic graphic_table graphicRef67913" href="/d/graphic/67913.html" rel="external">table 3</a>), and respiratory  (<a class="graphic graphic_table graphicRef58537" href="/d/graphic/58537.html" rel="external">table 4</a>) function. (See <a class="local">'Clinical symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Upper motor neuron symptoms result in slowness of movement, incoordination, and stiffness typically with relatively little overt weakness. (See <a class="local">'Upper motor neuron symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower motor neuron symptoms cause weakness, usually accompanied by atrophy  (<a class="graphic graphic_movie graphicRef53274" href="/d/graphic/53274.html" rel="external">movie 1</a>) and fasciculations  (<a class="graphic graphic_movie graphicRef66062" href="/d/graphic/66062.html" rel="external">movie 2</a> and <a class="graphic graphic_movie graphicRef63510" href="/d/graphic/63510.html" rel="external">movie 3</a>). Muscle cramps are also common. (See <a class="local">'Lower motor neuron symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive impairment, typically related to frontotemporal executive dysfunction, may precede or follow the onset of upper motor neuron and/or lower motor neuron dysfunction in patients with ALS. Frontotemporal dementia (FTD) may be associated with ALS in 15 to 50 percent of cases. (See <a class="local">'Cognitive symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autonomic symptoms may occur in ALS as the disease progresses. Constipation occurs frequently and is likely multifactorial. Dysphagia for thin liquids related to pharyngeal muscle weakness may lead to dehydration, which can exacerbate constipation. (See <a class="local">'Autonomic symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extrapyramidal symptoms and signs of parkinsonism may precede or follow the upper and lower motor neuron symptoms. These extrapyramidal features may include facial masking, tremor, bradykinesia, and postural instability. (See <a class="local">'Parkinsonism and supranuclear gaze palsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sensory impairment may occur in 20 to 30 percent of patients with ALS, but the sensory examination is usually normal. Nociceptive pain in ALS can arise from a variety of causes that include reduced mobility, muscle cramps, muscle spasticity, and comorbid conditions. (See <a class="local">'Sensory symptoms'</a> above and <a class="local">'Pain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical progression</strong> – ALS is a relentlessly progressive disorder with a clinical course that is generally linear. Symptoms typically spread within the segment of onset and then to other regions in a relatively predictable pattern. The progressive course of ALS eventually produces life-threatening neuromuscular respiratory failure and/or dysphagia. (See <a class="local">'Clinical patterns of progression'</a> above and <a class="local">'Life-threatening features'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary Neurology Series, 49, FA Davis Company, 1998.</li><li><a class="nounderline abstract_t">Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 Suppl 1:S6.</a></li><li><a class="nounderline abstract_t">Rowland LP. What's in a name? Amyotrophic lateral sclerosis, motor neuron disease, and allelic heterogeneity. Ann Neurol 1998; 43:691.</a></li><li><a class="nounderline abstract_t">Hirano A. Neuropathology of ALS: an overview. Neurology 1996; 47:S63.</a></li><li><a class="nounderline abstract_t">Adamek D, Tomik B, Pichór A, et al. The heterogeneity of neuropathological changes in amyotrophic lateral sclerosis. A review of own autopsy material. Folia Neuropathol 2002; 40:119.</a></li><li><a class="nounderline abstract_t">Ince PG, Evans J, Knopp M, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003; 60:1252.</a></li><li><a class="nounderline abstract_t">Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998; 24:104.</a></li><li><a class="nounderline abstract_t">Rowland LP. Amyotrophic lateral sclerosis. Curr Opin Neurol 1994; 7:310.</a></li><li><a class="nounderline abstract_t">Kim WK, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2009; 73:1686.</a></li><li><a class="nounderline abstract_t">Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve 2010; 41:161.</a></li><li><a class="nounderline abstract_t">Visser J, van den Berg-Vos RM, Franssen H, et al. Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 2007; 64:522.</a></li><li><a class="nounderline abstract_t">Tsuchiya K, Sano M, Shiotsu H, et al. Sporadic amyotrophic lateral sclerosis of long duration mimicking spinal progressive muscular atrophy exists: additional autopsy case with a clinical course of 19 years. Neuropathology 2004; 24:228.</a></li><li><a class="nounderline abstract_t">Singer MA, Statland JM, Wolfe GI, Barohn RJ. Primary lateral sclerosis. Muscle Nerve 2007; 35:291.</a></li><li><a class="nounderline abstract_t">D'Amico E, Pasmantier M, Lee YW, et al. Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD). Muscle Nerve 2013; 47:28.</a></li><li><a class="nounderline abstract_t">Chiò A, Calvo A, Moglia C, et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011; 82:740.</a></li><li><a class="nounderline abstract_t">Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry 2020; 91:373.</a></li><li><a class="nounderline abstract_t">Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006; 66:647.</a></li><li><a class="nounderline abstract_t">Gordon PH, Cheng B, Katz IB, et al. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Neurology 2009; 72:1948.</a></li><li><a class="nounderline abstract_t">Hassan A, Mittal SO, Hu WT, et al. Natural History of "Pure" Primary Lateral Sclerosis. Neurology 2021; 96:e2231.</a></li><li><a class="nounderline abstract_t">Paganoni S, De Marchi F, Chan J, et al. The NEALS primary lateral sclerosis registry. Amyotroph Lateral Scler Frontotemporal Degener 2020; 21:74.</a></li><li><a class="nounderline abstract_t">Heene R, Kolander D, Knisatschek H. [Chronic progressive spinobulbar spasticity (primary lateral sclerosis)]. Fortschr Neurol Psychiatr 1996; 64:192.</a></li><li><a class="nounderline abstract_t">Rowland LP. Primary lateral sclerosis: disease, syndrome, both or neither? J Neurol Sci 1999; 170:1.</a></li><li><a class="nounderline abstract_t">Amyotrophic lateral sclerosis and other motor neuron diseases. Adv Neurol 1991; 56:1.</a></li><li><a class="nounderline abstract_t">Tan CF, Kakita A, Piao YS, et al. Primary lateral sclerosis: a rare upper-motor-predominant form of amyotrophic lateral sclerosis often accompanied by frontotemporal lobar degeneration with ubiquitinated neuronal inclusions? Report of an autopsy case and a review of the literature. Acta Neuropathol 2003; 105:615.</a></li><li><a class="nounderline abstract_t">Tartaglia MC, Rowe A, Findlater K, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol 2007; 64:232.</a></li><li><a class="nounderline abstract_t">Karam C, Scelsa SN, Macgowan DJ. The clinical course of progressive bulbar palsy. Amyotroph Lateral Scler 2010; 11:364.</a></li><li><a class="nounderline abstract_t">Donaghy M. Classification and clinical features of motor neurone diseases and motor neuropathies in adults. J Neurol 1999; 246:331.</a></li><li><a class="nounderline abstract_t">Hu MT, Ellis CM, Al-Chalabi A, et al. Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1998; 65:950.</a></li><li><a class="nounderline abstract_t">Katz JS, Wolfe GI, Andersson PB, et al. Brachial amyotrophic diplegia: a slowly progressive motor neuron disorder. Neurology 1999; 53:1071.</a></li><li><a class="nounderline abstract_t">Couratier P, Truong C, Khalil M, et al. Clinical features of flail arm syndrome. Muscle Nerve 2000; 23:646.</a></li><li><a class="nounderline abstract_t">Wijesekera LC, Mathers S, Talman P, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009; 72:1087.</a></li><li><a class="nounderline abstract_t">Schito P, Ceccardi G, Calvo A, et al. Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study. J Neurol Neurosurg Psychiatry 2020; 91:1001.</a></li><li><a class="nounderline abstract_t">Alemà G, Brusa A, Pastorino P, Sacco G. [On 3 cases of the pseudopolyneuritic form of amyotrophic lateral sclerosis. Anatomic and electromyographic study]. J Neurol Sci 1967; 4:241.</a></li><li><a class="nounderline abstract_t">Wilbourn AJ. The "split hand syndrome". Muscle Nerve 2000; 23:138.</a></li><li><a class="nounderline abstract_t">Kuwabara S, Sonoo M, Komori T, et al. Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent, and specificity. Muscle Nerve 2008; 37:426.</a></li><li><a class="nounderline abstract_t">Eisen A, Kuwabara S. The split hand syndrome in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012; 83:399.</a></li><li><a class="nounderline abstract_t">Shoesmith CL, Findlater K, Rowe A, Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 2007; 78:629.</a></li><li><a class="nounderline abstract_t">Thakore NJ, Pioro EP. Laughter, crying and sadness in ALS. J Neurol Neurosurg Psychiatry 2017; 88:825.</a></li><li><a class="nounderline abstract_t">Tortelli R, Copetti M, Arcuti S, et al. Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP). J Neurol 2016; 263:316.</a></li><li><a class="nounderline abstract_t">Caress JB, Ciarlone SL, Sullivan EA, et al. Natural history of muscle cramps in amyotrophic lateral sclerosis. Muscle Nerve 2016; 53:513.</a></li><li><a class="nounderline abstract_t">Ringholz GM, Appel SH, Bradshaw M, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005; 65:586.</a></li><li><a class="nounderline abstract_t">Rippon GA, Scarmeas N, Gordon PH, et al. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol 2006; 63:345.</a></li><li><a class="nounderline abstract_t">Murphy J, Henry R, Lomen-Hoerth C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol 2007; 64:330.</a></li><li><a class="nounderline abstract_t">Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007; 6:994.</a></li><li><a class="nounderline abstract_t">Beeldman E, Raaphorst J, Klein Twennaar M, et al. The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry 2016; 87:611.</a></li><li><a class="nounderline abstract_t">Woolley SC, Strong MJ. Frontotemporal Dysfunction and Dementia in Amyotrophic Lateral Sclerosis. Neurol Clin 2015; 33:787.</a></li><li><a class="nounderline abstract_t">Crockford C, Newton J, Lonergan K, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology 2018; 91:e1370.</a></li><li><a class="nounderline abstract_t">Chiò A, Moglia C, Canosa A, et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology 2019; 93:e984.</a></li><li><a class="nounderline abstract_t">Olney RK, Murphy J, Forshew D, et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 2005; 65:1774.</a></li><li><a class="nounderline abstract_t">Piccione EA, Sletten DM, Staff NP, Low PA. Autonomic system and amyotrophic lateral sclerosis. Muscle Nerve 2015; 51:676.</a></li><li><a class="nounderline abstract_t">Toepfer M, Folwaczny C, Klauser A, et al. Gastrointestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1999; 1:15.</a></li><li><a class="nounderline abstract_t">Toepfer M, Folwaczny C, Lochmüller H, et al. Noninvasive (13)C-octanoic acid breath test shows delayed gastric emptying in patients with amyotrophic lateral sclerosis. Digestion 1999; 60:567.</a></li><li><a class="nounderline abstract_t">Toepfer M, Schroeder M, Klauser A, et al. Delayed colonic transit times in amyotrophic lateral sclerosis assessed with radio-opaque markers. Eur J Med Res 1997; 2:473.</a></li><li><a class="nounderline abstract_t">Kihara M, Takahashi A, Sugenoya J, et al. Sudomotor dysfunction in amyotrophic lateral sclerosis. Funct Neurol 1994; 9:193.</a></li><li><a class="nounderline abstract_t">Santos-Bento M, de Carvalho M, Evangelista T, Sales Luís ML. Sympathetic sudomotor function and amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2:105.</a></li><li><a class="nounderline abstract_t">Beck M, Giess R, Magnus T, et al. Progressive sudomotor dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002; 73:68.</a></li><li><a class="nounderline abstract_t">Oliveira Santos M, Castro I, Castro J, et al. Assessment of sympathetic sudomotor function in amyotrophic lateral sclerosis with electrochemical skin conductance. Clin Neurophysiol 2021; 132:2032.</a></li><li><a class="nounderline abstract_t">Brait K, Fahn S, Schwarz GA. Sporadic and familial parkinsonism and motor neuron disease. Neurology 1973; 23:990.</a></li><li><a class="nounderline abstract_t">Gilbert RM, Fahn S, Mitsumoto H, Rowland LP. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord 2010; 25:1868.</a></li><li><a class="nounderline abstract_t">McCluskey L, Vandriel S, Elman L, et al. ALS-Plus syndrome: non-pyramidal features in a large ALS cohort. J Neurol Sci 2014; 345:118.</a></li><li><a class="nounderline abstract_t">Moss HE, McCluskey L, Elman L, et al. Cross-sectional evaluation of clinical neuro-ophthalmic abnormalities in an amyotrophic lateral sclerosis population. J Neurol Sci 2012; 314:97.</a></li><li><a class="nounderline abstract_t">Hammad M, Silva A, Glass J, et al. Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology 2007; 69:2236.</a></li><li><a class="nounderline abstract_t">Feller TG, Jones RE, Netsky MG. Amyotrophic lateral sclerosis and sensory changes. Va Med Mon (1918) 1966; 93:328.</a></li><li><a class="nounderline abstract_t">Isaacs JD, Dean AF, Shaw CE, et al. Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder? J Neurol Neurosurg Psychiatry 2007; 78:750.</a></li><li><a class="nounderline abstract_t">Pugdahl K, Fuglsang-Frederiksen A, de Carvalho M, et al. Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study. J Neurol Neurosurg Psychiatry 2007; 78:746.</a></li><li><a class="nounderline abstract_t">Amoiridis G, Tsimoulis D, Ameridou I. Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology 2008; 71:779.</a></li><li><a class="nounderline abstract_t">Chiò A, Mora G, Lauria G. Pain in amyotrophic lateral sclerosis. Lancet Neurol 2017; 16:144.</a></li><li><a class="nounderline abstract_t">Handy CR, Krudy C, Boulis N, Federici T. Pain in amyotrophic lateral sclerosis: a neglected aspect of disease. Neurol Res Int 2011; 2011:403808.</a></li><li><a class="nounderline abstract_t">Goy ER, Carter J, Ganzini L. Neurologic disease at the end of life: caregiver descriptions of Parkinson disease and amyotrophic lateral sclerosis. J Palliat Med 2008; 11:548.</a></li><li><a class="nounderline abstract_t">Veronese S, Valle A, Chiò A, et al. The last months of life of people with amyotrophic lateral sclerosis in mechanical invasive ventilation: a qualitative study. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15:499.</a></li><li><a class="nounderline abstract_t">Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007; 68:1571.</a></li><li><a class="nounderline abstract_t">Ravits J, Laurie P, Fan Y, Moore DH. Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology 2007; 68:1576.</a></li><li><a class="nounderline abstract_t">Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012; 135:847.</a></li></ol></div><div id="topicVersionRevision">Topic 5136 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary Neurology Series, 49, FA Davis Company, 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9851643" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis of amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9629837" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : What's in a name? Amyotrophic lateral sclerosis, motor neuron disease, and allelic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8858053" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neuropathology of ALS: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12572917" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The heterogeneity of neuropathological changes in amyotrophic lateral sclerosis. A review of own autopsy material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707426" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9634206" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7952238" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917992" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Study of 962 patients indicates progressive muscular atrophy is a form of ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20082312" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Progressive muscular atrophy and other lower motor neuron syndromes of adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420313" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Disease course and prognostic factors of progressive muscular atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15484701" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sporadic amyotrophic lateral sclerosis of long duration mimicking spinal progressive muscular atrophy exists: additional autopsy case with a clinical course of 19 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17212349" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Primary lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169452" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21402743" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32029539" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Primary lateral sclerosis: consensus diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534101" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The natural history of primary lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487653" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33637635" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Natural History of "Pure" Primary Lateral Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32915077" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The NEALS primary lateral sclerosis registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675141" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [Chronic progressive spinobulbar spasticity (primary lateral sclerosis)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10540028" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Primary lateral sclerosis: disease, syndrome, both or neither?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1853751" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Amyotrophic lateral sclerosis and other motor neuron diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12734667" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Primary lateral sclerosis: a rare upper-motor-predominant form of amyotrophic lateral sclerosis often accompanied by frontotemporal lobar degeneration with ubiquitinated neuronal inclusions? Report of an autopsy case and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296839" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132084" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The clinical course of progressive bulbar palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10399861" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Classification and clinical features of motor neurone diseases and motor neuropathies in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854987" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10496268" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Brachial amyotrophic diplegia: a slowly progressive motor neuron disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716778" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical features of flail arm syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19307543" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Natural history and clinical features of the flail arm and flail leg ALS variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32651246" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6068314" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : [On 3 cases of the pseudopolyneuritic form of amyotrophic lateral sclerosis. Anatomic and electromyographic study].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10590421" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The "split hand syndrome".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18236469" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dissociated small hand muscle atrophy in amyotrophic lateral sclerosis: frequency, extent, and specificity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22100761" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The split hand syndrome in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088331" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prognosis of amyotrophic lateral sclerosis with respiratory onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28572273" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Laughter, crying and sadness in ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26588919" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26332705" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Natural history of muscle cramps in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116120" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevalence and patterns of cognitive impairment in sporadic ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16533961" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An observational study of cognitive impairment in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17353375" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17945153" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cognitive impairment in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283685" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The cognitive profile of ALS: a systematic review and meta-analysis update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26515622" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Frontotemporal Dysfunction and Dementia in Amyotrophic Lateral Sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30209236" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31409738" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cognitive impairment across ALS clinical stages in a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344521" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The effects of executive and behavioral dysfunction on the course of ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25211238" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Autonomic system and amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12365061" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Gastrointestinal dysfunction in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10545728" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Noninvasive (13)C-octanoic acid breath test shows delayed gastric emptying in patients with amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9385117" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Delayed colonic transit times in amyotrophic lateral sclerosis assessed with radio-opaque markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7883205" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sudomotor dysfunction in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11675871" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sympathetic sudomotor function and amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12082050" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Progressive sudomotor dysfunction in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34284237" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Assessment of sympathetic sudomotor function in amyotrophic lateral sclerosis with electrochemical skin conductance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4737691" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sporadic and familial parkinsonism and motor neuron disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20669307" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25086858" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : ALS-Plus syndrome: non-pyramidal features in a large ALS cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22192877" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cross-sectional evaluation of clinical neuro-ophthalmic abnormalities in an amyotrophic lateral sclerosis population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071143" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5934354" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Amyotrophic lateral sclerosis and sensory changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575021" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575020" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765658" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27964824" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pain in amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21766021" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pain in amyotrophic lateral sclerosis: a neglected aspect of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18454605" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Neurologic disease at the end of life: caregiver descriptions of Parkinson disease and amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24863495" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The last months of life of people with amyotrophic lateral sclerosis in mechanical invasive ventilation: a qualitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485643" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Focality of upper and lower motor neuron degeneration at the clinical onset of ALS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485644" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271664" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A proposed staging system for amyotrophic lateral sclerosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
